Olanzapine withdrawal/discontinuation-induced hyperthermia in rats

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 7, 2007, Pages 1500-1503

  Goudie, Andrew J ^a   Cole, Jon C ^a   Sumnall, Harry R ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

Author keywords

Antipsychotic; Discontinuation; Olanzapine; Relapse; Tolerance; Withdrawal

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE;

ARTICLE; CONTROLLED STUDY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; HYPERTHERMIA; NONHUMAN; PSYCHOSIS; RAT; RELAPSE;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY TEMPERATURE; DRUG TOLERANCE; FEMALE; FEVER; RATS; RATS, WISTAR; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 34548155756     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.07.007     Document Type: Article

References (25)

1. Albaugh L., Henry C., Bello N., Hajnal A., Lynch S., Halle B., et al. Hormonal and metabolic effects of olanzapine and clozapine related to body weight. Obesity 14 (2006) 36-51
2. Aravagiri M., Teper Y., and Marder S. Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 999 20 (1999) 369-377
3. Baldessarini R., Viguera A., and Tondo L. Discontinuing psychotropic agents. J Psychopharmacol 13 (1999) 292-293
4. Baldessarini R., Tondo L., and Viguera A. Discontinuing lithium maintenance treatment in bipolar disorder: risks and implications. Bipolar Disord 1 (1999) 17-24
5. Baptista T. Hypophagia after long term administration of sulpiride in adult female rats: a model of D2 dopamine receptor supersensitivity. Med Hypotheses 30 (1989) 5-8
6. Baptista T., Mata A., Teneud L., De Quijada M., Han H.-.W., and Hernandez L. Effects of long term administration of clozapine on body weight and food intake in rats. Pharmacol Biochem Behav 45 (1993) 51-54
7. Baptista T., Teneud L., and Hernandez L. Enhancement of amphetamine anorexia after chronic sulpiride administration in rats. Pharmacol Biochem Behav 45 (1993) 45-49
8. Blessing W. Clozapine and olanzapine, but not haloperidol, reverse cold-induced and lipopolysaccharide-induced cutaneous vasoconstriction. Psychopharmacology 175 (2004) 481-493
9. Cooper G., Pickavance L., Wilding J., Halford J., and Goudie A. A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology 181 (2005) 80-89
10. Fernandez H., Trieschmann M., and Okun M. Rebound psychoses: effect of discontinuation of antipsychotics in Parkinson's disease. Mov Disord 20 (2005) 104-115
11. Goudie A. What is the clinical significance of the discontinuation syndrome seen with clozapine?. J Psychopharmacol 14 (2000) 188-192
12. Goudie A., Smith J., Robertson A., and Cavanagh C. Clozapine as a drug of dependence. Psychopharmacology 142 (1999) 369-374
13. Goudie A., Smith J., and Halford J. Characterization of olanzapine induced weight gain in rats. J Psychopharmacol 16 (2002) 291-296
14. Goudie A., Cole J., and Sumnall H. Olanzapine and JL 13 induce cross-tolerance to the clozapine discriminative stimulus in rats. Behav Pharmacol 18 (2007) 9-17
15. Grassi B., Ferrari R., Epifani M., Dragoni C., Cohen S., and Scarone S. Clozapine lacks previous clinical efficacy when restarted after a period of discontinuation. A case series. Eur Neuropsychopharmacol 9 (1999) 479-481
16. Healy D., and Tranter R. Pharmacological stress/diathesis syndromes. J Psychopharmacol 13 (1999) 287-290
17. Meltzer H., Lee M., Ranjan R., Mason E., and Cola P. Relapse following clozapine withdrawal. Psychopharmacology 124 (1996) 176-187
18. Miodownik C., Lerner V., Kibari A., Toder D., and Cohen H. The effect of sudden clozapine discontinuation on management of schizophrenic patients: a retrospective controlled study. J Clin Psychiatry 67 (2006) 1204-1208
19. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand 114 (2006) 3-13
20. Patil B., Kulkarni N., and Unger B. Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain. Eur J Pharmacol 551 (2006) 112-115
21. Pickar D., and Bartko J. Effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment resistant schizophrenia. Am J Psychiatry 160 (2003) 1133-1138
22. Samaha A., Seeman P., Stewart J., Rajabi H., and Kapur S. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 27 (2007) 2979-2986
23. Stanford J., and Fowler S. Similarities and differences between the subchronic and withdrawal effects of clozapine and olanzapine on forelimb steadiness. Psychopharmacology 132 (1997) 408-414
24. Tollefson G., Dellva M., Mattler C., Kane J., Wirshing D., and Kinon B. Controlled double-blind investigation of clozapine discontinuation symptoms with conversion to either olanzapine or placebo. J Clin Psychopharmacol 19 (1999) 435-443
25. Tranter R., and Healey D. Neuroleptic discontinuation syndromes. J Psychopharmacol 12 (1998) 401-406